Study: Lilly’s Zepbound cut risk of diabetes by 94% in obese people
The longest continuous study of Indianapolis-based Lilly’s drug Zepbound to date included more than 1,000 patients.
Pharmaceutical
Articles
Lilly opens new 12-story, $700M R&D center in Boston
Lilly is moving about 200 scientists and researchers who had worked in nearby Cambridge, Massachusetts, to the new center, and plans to add about 300 employees.
Purdue, Lilly establish medical-focused research center
The Eli Lilly and Co. and Purdue University Research Alliance Center involves more than 50 researchers and 65 graduate students.
Novo Nordisk’s Wegovy sales hit by competition from Eli Lilly
Novo is vying with Indianapolis-based Lilly for supremacy in the pharmaceutical industry’s fastest-growing new business, obesity drugs. The market is expected to reach $130 billion by the end of the decade.
Fast-growing MBX Biosciences raises another $63.5 million in funding
MBX is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity.
Lilly CEO says weight-loss drug shortage to end ‘very soon’
Meanwhile, Lilly announced that Zepbound improved the long-term health of patients with obesity-related heart failure in a study.
Novo’s diabetes drug shows mixed results in Alzheimer’s trial
Victoza yielded mixed results in a mid-stage study of Alzheimer’s disease, failing to meet its primary goal while showing hints that larger trials of similar drugs may be successful.
Lilly inches toward rare $1 trillion market-value distinction
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
Hims & Hers adds longtime Novo executive to board amid weight-loss bet
Shortages of brand-name drugs made by Novo and Eli Lilly and Co. have allowed pharmacies to make what are essentially copies, and telehealth companies like Hims are selling them to patients at a steep discount.
Lilly shares slide 7% after Roche announces obesity pill test results
The Roche drug is a once-daily pill, compared to Lilly’s tirzepatide, sold under the brand names Mounjaro (for diabetes) and Zepbound (for obesity), which is a once-weekly shot.
INCOG BioPharma investing additional $125M on Fishers campus
The expansion plan includes construction of a 100,000-square-foot building on its corporate campus and the addition of 100 jobs.
Stevanato commits to paying Fishers employees a living wage
Stevanato, an Italian-based life sciences company that makes glass vials and syringes for pharmaceuticals, has committed to paying employees at its new Fishers facility no less than $70,000 annually.
UPDATE: FDA approves Lilly drug that can modestly slow Alzheimer’s disease
Eli Lilly’s drug—Kisunla, the brand name for donanemab—is one of the few treatments developed for Alzheimer’s that modifies the underlying disease and will join just one other drug, Leqembi, on the commercial market.
The Supreme Court rejects a nationwide opioid settlement with OxyContin maker Purdue Pharma
The decision also could affect other major bankruptcies, including the $2.4 billion bankruptcy plan for the Boy Scouts of America that has been approved by a federal judge, lawyers said.
Weight-loss-drug frenzy lures rich Indians to brave the gray market
The race to score blockbuster weight-loss drugs like Eli Lilly’s Mounjaro and Zepbound is pushing one of the world’s largest population of people with obesity to creative lengths.
Lilly files suit against more spas, weight-loss centers selling knockoff version of its popular drugs
The Indianapolis-based drugmaker said Thursday it was taking legal action against at least six additional medical spas and weight loss centers that it claimed are selling counterfeit and compounded versions of tirzepatide, the active ingredient in Lilly’s diabetes treatment Mounjaro and weight-loss treatment Zepbound.
Fishers approves incentives agreement for pharmaceutical logistics company
A Philadelphia-based company involved in drug delivery and logistics is working with the city of Fishers on an economic development deal that could result in a $40 million investment and 350 new jobs.
Lilly and subsidiary Point Biopharma accused of patent infringement of cancer drugs
At issue is whether a drug developed by Point Biopharma, based in Indianapolis, infringed on a patent issued in 2020 and assigned to Purdue Research Foundation.
Drug shortages keep growing. Older, injectable medicines among most vulnerable.
Total active shortages hit an all-time high of 323 in this year’s first quarter, according to the University of Utah Drug Information Service. That’s up about 86% since 2017.
Michigan’s largest insurer to drop weight-loss drug coverage
Obesity drugs such as Novo’s Wegovy and Lilly’s Zepbound are exploding in popularity. But with list prices of $1,000 a month or more, insurers are balking at the prices and trying to limit how widely they’re used.